12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ATX-101: Additional Phase III data

Additional data from the double-blind, European Phase III Study 16 trial in 363 patients showed that monthly 2 mg/cm 2 ATX-101 for up to 4 treatment cycles significantly improved mean CR-SMFRS score, a co-primary endpoint, by 0.9 points from baseline to week 24 vs. 0.22 points for placebo (p<0.001). Additionally, 66.1% of patients receiving ATX-101 achieved an undisclosed pre-defined categorical change using SSRS score at week 24 vs. 28.7% for placebo (p<0.001)....

Read the full 340 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >